“Drug Reaction with Eosinophilia and Systemic Symptoms” (DRESS): Long-term Outcomes Based on Severity – A Cohort Study
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0310Keywords:
drug reaction with eosinophilia and systemic symptoms, DRESS, sequelae, severity, organ involvementAbstract
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug-induced reaction characterized by exanthema, eosinophilia and organ involvement. Patients reported sequelae comprising skin or organ alterations and autoimmune diseases. We investigated long-term complications of patients included in the German Registry of severe skin reactions between 2003 and 2023 with a definite or probable diagnosis of DRESS using a follow-up questionnaire. Cases were classified by severity (mild, moderate-to-severe) employing 2 scores (drug-induced liver injury [DILI] and acute kidney injury [AKI]). In total, 36/61 questionnaires (59%) were analysed revealing an equal distribution: 18 mild and 18 moderate-to-severe cases. All patients experienced long-term complications. Skin disorders occurred in 81%, mucosal problems in 31% and hair/nail complications in 43%. Severity groups were equally affected, whereas laboratory abnormalities appeared more often in moderate-to-severe cases. Haematological abnormalities were most frequently observed (94%), followed by elevated liver enzymes (88%) and impaired renal function parameters (31%). Alterations of HbA1c occurred in 16% and abnormal thyroid function in 19%, including 2 cases of Graves’ disease. Intolerance reactions to other medication were observed in 27% of cases, explaining fear of further medication (51%) and resulting avoidance behaviour (49%).
Downloads
References
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250–257. DOI: https://doi.org/10.1016/S1085-5629(96)80038-1
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071–1080. DOI: https://doi.org/10.1111/bjd.12501
Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146: 1373–1379. DOI: https://doi.org/10.1001/archdermatol.2010.198
Shiohara T, Kano Y, Takahashi R, Ishida T, Mizukawa Y. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy 2012; 97: 122–138. DOI: https://doi.org/10.1159/000335624
Skowron F, Bensaid B, Balme B, Depaepe L, Kanitakis J, Nosbaum A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol 2015; 29: 2199–2205. DOI: https://doi.org/10.1111/jdv.13212
Lee JY, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. Int J Dermatol 2017; 56: 944–951. DOI: https://doi.org/10.1111/ijd.13667
Saltzstein SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically pathologically malignant lymphomas. Cancer 1959; 12: 164–182. DOI: https://doi.org/10.1002/1097-0142(195901/02)12:1<164::AID-CNCR2820120122>3.0.CO;2-Y
Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome. Med Clin N 2010; 94: 743–759. DOI: https://doi.org/10.1016/j.mcna.2010.03.004
Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol 2021; 77: 275–289. DOI: https://doi.org/10.1007/s00228-020-03005-9
Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2: 46ra62. DOI: https://doi.org/10.1126/scitranslmed.3001116
Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998; 134: 1113–1117. DOI: https://doi.org/10.1001/archderm.134.9.1113
Descamps V. Drug reaction with eosinophilia and systemic symptoms and thyroiditis: human herpesvirus-6, the possible common link. Br J Dermatol 2013; 169: 952. DOI: https://doi.org/10.1111/bjd.12456
Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083–1084. DOI: https://doi.org/10.1111/j.1365-2133.2007.07807.x
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609–611. DOI: https://doi.org/10.1111/j.1365-2133.2006.07704.x
Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 2013; 68: 721–728. DOI: https://doi.org/10.1016/j.jaad.2012.10.017
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806–815. DOI: https://doi.org/10.1038/clpt.2011.58
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120: c179–84. DOI: https://doi.org/10.1159/000339789
Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, et al. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol 2020; 30: 229–253. DOI: https://doi.org/10.18176/jiaci.0480
Huang YS, Wu CY, Chang TT, Peng CY, Lo GH, Hsu CW, et al. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int 2021; 41: 2671–2680. DOI: https://doi.org/10.1111/liv.14990
Medina-Cáliz I, Sanabria-Cabrera J, Villanueva-Paz M, Aukštikalnė L, Stephens C, Robles-Díaz M, et al. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. Arch Toxicol 2024; 98: 303–325. DOI: https://doi.org/10.1007/s00204-023-03630-0
Tharpe N. Adverse drug reactions in women’s health care. J Midwife Womens Health 2011; 56: 205–213. DOI: https://doi.org/10.1111/j.1542-2011.2010.00050.x
Chiang PH, Ng CY, Kuo TT, Hui RCY, Chen CB, Lu CW, et al. Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome. J Dermatol 2021; 48: 92–95. DOI: https://doi.org/10.1111/1346-8138.15562
Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012; 7: e37513. DOI: https://doi.org/10.1371/journal.pone.0037513
Paulmann M, Mockenhaupt M. Schwere Hautreaktionen: klinisches Bild, Epidemiologie, Ätiologie, Pathogenese und Therapie. Allergo J 2019; 28: 16–34. DOI: https://doi.org/10.1007/s15007-019-1973-z
Lee JW, Yu DA, Cho S, Youn SW, Kwon O. Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS): a multicentric retrospective case series. J Dermatol 2023; 50: 814–819. DOI: https://doi.org/10.1111/1346-8138.16715
Iskandarli M, Ozturk G. Alopecia areata and vitiligo as a long-term sequelae of drug reaction with eosinophilia and systemic symptoms syndrome. Indian J Dermatol 2016; 61: 238. DOI: https://doi.org/10.4103/0019-5154.177781
Allanore L, Roujeau JC. Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis. In: Pichler WJ, editor. Drug Hypersensitivity. Basel: Karger; 2007: p. 267–277. doi: 10.1159/000104206. DOI: https://doi.org/10.1159/000104206
Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, Beneton N, Jidar K, Barbaud A, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010; 20: 68–73. DOI: https://doi.org/10.1684/ejd.2010.0821
Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168: 555–562. DOI: https://doi.org/10.1111/bjd.12125
Descamps V, Ben Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2010; 137: 703–708. DOI: https://doi.org/10.1016/j.annder.2010.04.024
Lee T, Lee YS, Yoon SY, Kim S, Bae YJ, Kwon HS, et al. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol 2013; 69: 407–415. DOI: https://doi.org/10.1016/j.jaad.2013.03.024
Lin IC, Yang HC, Strong C, Yang CW, Cho YT, Chen KL, et al. Liver injury in patients with DRESS: a clinical study of 72 cases. J Am Acad Dermatol 2015; 72: 984–991. DOI: https://doi.org/10.1016/j.jaad.2015.02.1130
Dagnon da Silva M, Domingues SM, Oluic S, Radovanovic M, Kodela P, Nordin T, et al. Renal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of 71 cases. J Clin Med 2023; 12: 4576. DOI: https://doi.org/10.3390/jcm12144576
Torroba Sanz B, Mendez Martínez E, Cacho Asenjo E, Aquerreta Gonzalez I. Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine. Eur J Hosp Pharm 2021; 28: 285–288. DOI: https://doi.org/10.1136/ejhpharm-2019-002149
Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol 2015; 42: 276–282. DOI: https://doi.org/10.1111/1346-8138.12770
Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68: 459–465. DOI: https://doi.org/10.1016/j.jaad.2012.08.009
Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves’ disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab 2020; 34: 101387. DOI: https://doi.org/10.1016/j.beem.2020.101387
Kano Y, Shiohara T. Long-term outcome of patients with severe cutaneous adverse reactions. Dermatol Sin 2013; 31: 211–216. DOI: https://doi.org/10.1016/j.dsi.2013.09.004
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
